anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The absence of a natural animal model is one of the main challenges in Alzheimer's disease research. Despite the challenges of using nonhuman primates in studies, these animals can bridge mouse models and humans, as nonhuman primates are phylogenetically closer to humans and can spontaneously develop AD-type pathology. The capuchin monkey, a New World primate, has recently attracted attention due to its skill in creating and using instruments. We analyzed one capuchin brain using structural 7 T MRI and performed a neuropathological evaluation of three animals. Alzheimer-type pathology was found in the two of the capuchins. Widespread β-amyloid pathology was observed, mainly in focal deposits with variable morphology and a high density of mature plaques. Notably, plaque-associated dystrophic neurites associated with disruption of axonal transport and early cytoskeletal alteration were frequently found. Unlike in other species of New World monkeys, cerebral arterial angiopathy was not the predominant form of β-amyloid pathology. Additionally, abnormal aggregates of hyperphosphorylated tau, resembling neurofibrillary pathology, were observed in the temporal and frontal cortex. Astrocyte hypertrophy surrounding plaques was found, suggesting a neuroinflammatory response. These findings indicate that aged capuchin monkeys can spontaneously develop Alzheimer-type pathology, indicating that they may be an advantageous animal model for research in Alzheimer's disease.
Methods and devices useful for monitoring a patient and for monitoring and displaying the value of a physiological parameter are disclosed. In one embodiment, a user interface for a medical monitoring device is provided. The user interface can have a monitoring screen with a current value screen and a trend screen. The current value screen can display a graphical representation of a value of a physiological parameter over time, e.g., over a first time period, and the trend screen can display a graphical representation of a mean value of the parameter over time, e.g., over a second time period. In some embodiments, an out-of-limit condition for the parameter can be indicated with shading. In yet other embodiments, the user interface can provide an event marking screen, which can provide the ability to mark events on a historical trend screen that displays a value of the parameter over time.
A premade ceramic dental implant abutment includes a ceramic abutment having at the top a support region intended for receiving a mating prosthetic build-up construction with a surface feature to inhibit rotation of said construction, and at the bottom, an implant contact region with geometry to connect to the implant. The ceramic abutment has a passageway extending therethrough. The passageway may narrow to form a shoulder that is made entirely of ceramic. A head of a screw seats entirely on the shoulder. The ceramic abutment has a supragingival region for protruding beyond the gingiva and a subgingival end for extending into the gingiva. The ceramic abutment may be free of metal. Also, the premade ceramic abutment may be designed to be augmented by cementing additional ceramic material such as a ceramic prosthesis onto the ceramic abutment.
The present invention is an intravenous infusion-typed methyl mylabris amine injection for the tumor treatment. The present invention is a new generation injection preparation for tumor treatment, which has very good therapy function in antitumor and leukocyte rising. The injection preparation comprises the injection liquid and the freezing dry powder preparation. The propanediol or one kind or a plurality of kinds of the propanediol with the ethanol, the glycerol and the polyethylene glycol are taken as the solubilizer. The double solvents composed by the water and the injection are taken as the solvent in order to enhance solubility and stability of the solute. The methyl mylabris amine injection of the present invention can be prepared in conventional method. The injection preparation of The present invention is wide spectrum antineoplastic agents, which is applicable for treatment of a plurality of  tumor comprising primary liver cancer, lung cancer, esophagus cancer, nasopharynx cancer, malignant lymphoma, bladder cancer, malignant tumor. The present invention is also applicable for hepatitis, liver cirrhosis and HBV carriers.
PURPOSE:To provide an antibacterial agent by modifying the surface of fine partidle of 2-mercaptopyridine-N-oxide polyvalent metal salt with an aqueous solvent containing cationic polymer compound and an inorganic salt. CONSTITUTION:The objective surface-modified antibacterial agent can be pro duced by treating fine particle 2-mercaptopyridine-N-oxide polyvalent metal salt wherein the particle having particle diameter of <=0.2mum accounts for >=50wt%, with an aqueous solution containing 0.1-60wt% cationic polymer compound [e.g. a copolymer of dimethyl diallyl ammonium halide and acrylamide and expressed by the formula I or II (R25 and R26 are H or methyl; X is halogen; l+m4 is 180-2,000)] and 0.1-25wt% inorganic salt. A hair treat ment composition such as shampoo, rinse, hair lotion, etc. can be prepared by using the above agent at a concentration of 0.01-10wt%. An anionic surfac tant, amphoteric surfactant, etc., is used as the substrate of the above hair- treatment composition.
Deregulated cyclin-dependent kinase 5 (Cdk5) activity closely correlates with hyperphosphorylated tau, a common pathology found in neurodegenerative diseases. Previous postmortem studies had revealed increased Cdk5 immunoreactivity in amyotrophic lateral sclerosis (ALS); hence, we investigated the effects of Cdk5 inhibition on ALS model mice and neurons in this study. For the in vitro study, motor neuron cell lines with wild-type superoxide dismutase 1 (SOD1) or SOD1G93A and primary neuronal cultures from SOD1G93A transgenic (TG) mice or non-TG mice were compared for the expression of proteins involved in tau pathology, neuroinflammation, apoptosis, and neuritic outgrowth by applying Cdk5-small interfering RNA or Cdk5-short hairpin RNA (shRNA). For the in vivo study, SOD1G93A mice and non-TG mice were intrathecally injected with adeno-associated virus 9 (AAV9)-scramble (SCR)-shRNA or AAV9-Cdk5-shRNA at the age of 5 weeks. Weight and motor function were measured three times per week from 60 days of age, longevity was evaluated, and the tissues were collected from 90-day-old or 120-day-old mice. Neurons with SOD1G93A showed increased phosphorylated tau, attenuated neuritic growth, mislocalization of SOD1, and enhanced neuroinflammation and apoptosis, all of which were reversed by Cdk5 inhibition. Weights did not show significant differences among non-TG and SOD1G93A mice with or without Cdk5 silencing. SOD1G93A mice treated with AAV9-Cdk5-shRNA showed significantly delayed disease onset, delayed rotarod failure, and prolonged survival compared with those treated with AAV9-SCR-shRNA. The brain and spinal cord of SOD1G93A mice intrathecally injected with AAV9-Cdk5-shRNA exhibited suppressed tau pathology, neuroinflammation, apoptosis, and an increased number of motor neurons compared to those of SOD1G93A mice injected with AAV9-SCR-shRNA. Cdk5 inhibition could be an important mechanism in the development of a new therapeutic strategy for ALS.
Subjects received placebo on Day1 will receive a single IV infusion of AK101 at Week8 along with matching subcutaneous placebo (to maintain the blind). And subjects will be randomized at Week8 to receive low-dose AK101 subcutaneously every 8 weeks along with matching placebo subcutaneously (to maintain the blind).
Patients in the Monitored group "M", the NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume.
A telepresence robot may include a drive system, a control system, an imaging system, and a mapping module. The mapping module may access a plan view map of an area and tags associated with the area. In various embodiments, each tag may include tag coordinates and tag information, which may include a tag annotation. A tag identification system may identify tags within a predetermined range of the current position and the control system may execute an action based on an identified tag whose tag information comprises a telepresence robot action modifier. The telepresence robot may rotate an upper portion independent from a lower portion. A remote terminal may allow an operator to control the telepresence robot using any combination of control methods, including by selecting a destination in a live video feed, by selecting a destination on a plan view map, or by using a joystick or other peripheral device.
SCOPE: The global prevalence of obesity has significantly increased, presenting a major health challenge. High-fat diet (HFD)-induced obesity is closely related to the disease severity of psoriasis, but the mechanism is not fully understood.
METHODS AND RESULTS: The study utilizes the HFD-induced obesity model along with an imiquimod (IMQ)-induced psoriasis-like mouse model (HFD-IMQ) to conduct transcriptomics and metabolomic analyses. HFD-induced obese mice exhibits more severe psoriasis-like lesions compared to normal diet (ND)-IMQ mice. The expression of genes of the IL-17 signaling pathway (IL-17A, IL-17F, S100A9, CCL20, CXCL1) is significantly upregulated, leading to an accumulation of T cells and neutrophils in the skin. Moreover, the study finds that there is an inhibition of the branched-chain amino acids (BCAAs) catabolism pathway, and the key gene branched-chain amino transferase 2 (Bcat2) is significantly downregulated, and the levels of leucine, isoleucine, and valine are elevated in the HFD-IMQ mice. Furthermore, the study finds that the peroxisome proliferator-activated receptor gamma (PPAR γ) is inhibited, while STAT3 activity is promoted in HFD-IMQ mice.
CONCLUSION: HFD-induced obesity significantly amplifies IL-17 signaling and exacerbates psoriasis, with a potential role played by Bcat2-mediated BCAAs metabolism. The study suggests that BCAA catabolism and PPAR γ-STAT3 exacerbate inflammation in psoriasis with obesity.
BACKGROUND/AIMS: Non-alcoholic fatty liver disease (NAFLD), now the most common chronic liver worldwide, has become a significant public health concern. This study aims to analyze the evolving epidemiology of NAFLD in South Korea.
METHODS: We utilized claim data from the Korean National Health Insurance Service from 2010 to 2022 to analyze NAFLD's incidence, prevalence, and progression.
RESULTS: From 2010 to 2022, the incidence and prevalence rates of NAFLD each increased from 1.87% to 4.47% and from 10.49% to 17.13%, respectively. The differences in prevalence rates between urban and rural areas were minimal in 2012 and 2022, yet both areas showed significant increases in the prevalence of NAFLD over the decade. The NAFLD group had a higher prevalence of comorbidities compared to the control group, and the most common comorbid condition was hypertension. Moreover, the ten-year incidence rates of malignancy, heart disease, and stroke in the NAFLD group were 13.42%, 15.72%, and 8.36%, respectively, which were significantly higher than those in the control group. The incidence rates of cirrhosis and hepatocellular carcinoma in NAFLD over 10 years were 2.22% and 0.77%, respectively. The total medical costs of NAFLD patients more than doubled over ten years and were all significantly higher than those of the control group.
CONCLUSION: A significant increase in NAFLD prevalence and its impact on healthcare utilization was observed in South Korea. With NAFLD leading to serious liver diseases and increased healthcare costs, integrated care strategies that include both medical treatment and lifestyle modifications are essential.
* Inform patients that, if FLECTOR PATCH begins to peel-off, the edges of the patch may be taped down. If problems with adhesion persist, patients may overlay the patch with a mesh netting sleeve, where appropriate (e.g. to secure patches applied to ankles, knees, or elbows). The mesh netting sleeve (e.g. Curad® Hold Tite™, Surgilast® Tubular Elastic Dressing) must allow air to pass through and not be occlusive (non-breathable). 
  * Do not apply FLECTOR PATCH to non-intact or damaged skin resulting from any etiology e.g. exudative dermatitis, eczema, infected lesion, burns or wounds. 
  * Do not wear a FLECTOR PATCH when bathing or showering. 
  * Wash your hands after applying, handling or removing the patch. 
  * Avoid eye contact
  * Do not use combination therapy with FLECTOR PATCH and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations.
The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
PURPOSE:To obtain a preparation having good absorptivity of chlorophyll having bactericidal action, etc., into interior of the body and excellent chlorophyll effect by cooperative action with protein by kneading a product obtained by ultrasonic treatment of a chlorophyll-containing substance in ethanol solution and a protein-containing substance. CONSTITUTION:Chloroplast plant, green alga or dung of silk worm, etc., is used as raw material of chlorophyll and said raw material is dipped in aqueous solution of ethanol, preferably concentrated aqueous solution of >=80%, then ultrasonic wave is irradiated to said dipped solution and simultaneously stirred with stirring wing. Timing of ultrasonic wave irradiation is about 60-200min. Resultant chlorophyll-extracted ethanol solution is filtered and residue of raw material is removed, then collected. Next, a protein-containing substance such as protein G, preferably >=50% protein-containing is added to said chlorophyll- extracted ethanol solution, kneaded and formed as granular, etc., using dryer, etc. Mixing ratio of chlorophyll solution and protein-containing substance is 1:1, preferably 3:1.
PURPOSE:To provide the subject remedy containing pleuromutilin derivative as an active component, exhibiting excellent antibacterial activity against bacteria of genus Renibacterium such as streptococci and free from cross resistance between various conventional antibiotics. CONSTITUTION:The objective agent contains, as an active component, a pleuromutilin derivative which is a free compound, an acid addition salt or a quaternary salt of a compound of formula [R1 is ethyl or vinyl; R2 is 5-membered saturated heterocyclic group or amino(OH-substituted)alkyl], e.g. 14- deoxy-14[(2-D-valylamino-isobutyl)thioacetoxime]-mutilin. The pleuromutilin derivative can be synthesized by the chemical modification of a precursor pleuromutilin which is a diterpene antibiotic substance derived from culture liquid of Pleurotus mutilus. The agent is administered in the form of powder, liquid, feed, etc. It is useful for the prevention and remedy of bacterial disease of fish such as streptococciosis and bacterial kidney disease.
The present invention relates to a method for preparing, based on Internet of Thing (IOT), a black anthocyanin concentration serving as new bio drug including a nature substance by including a black bean seed hull, a component for installing a personal computer (PC), a temperature sensor having a port to introduce the black bean seed hull, a heading wire, a 1% alcohol solution device, a vapor pipe transfer tube connected with the 1% alcohol solution device, a 4°C cooling water device provided therein with a temperature sensor vapor transfer pipe linked with the vapor pipe transfer tube, and a black anthocyanin concentration storage tank. Various control operations including an on/off operation are performed through the PC connected with the 4°C cooling water device provided therein with the temperature sensor vapor transfer pipe connected with the vapor pipe transfer tube connected with the temperature sensor, the heating wire and the 1% alcohol solution device. Conditions of the temperature of 25°C for 10 hours, the temperature of 40°C for two hours, and the cooling temperature of 4°C for 12 hours are set for the alcohol solution. Then, after identifying real-time information on the heating result, the black bean seed hull, which is heated to 25°C, is introduced at the ratio of 1 kg of black bean seed hull and 5L of a 1% alcohol solution, through the port of the 1% alcohol solution device of the temperature sensor. The black bean seed hull is dipped for 10 hours and then an anthocyanin solution is extracted. The vapor of the anthocyanin solution, which is produced through 2-hour heating at the temperature of 40°C, passes through the vapor pipe transfer tube and the vapor transfer pipe of the 4°C cooling water device having the temperature sensor vapor transfer pipe therein, thereby preparing the black anthocyanin concentration serving as the new bio drug including the natural substance. The prepared black anthocyanin concentration is stored into the black anthocyanin concentration storage tank. The black anthocyanin concentration serving as the new bio drug including the natural substance has an active effect in anticancer, antihypertensive, and antioxidant physiological action, produces preventive effect and excellent effects in cancer, dementia, diabetes, obesity, skin disease, and vision improvement, and increases customer satisfaction.
The high prevalence of major depressive disorder (MDD) frequently imposes severe constraints on psychosocial functioning and detrimentally impacts overall well-being. Despite the growing interest in the hypothesis of mitochondrial dysfunction, the precise mechanistic underpinnings and therapeutic strategies remain unclear and require further investigation. In this study, an MDD model was established in mice using lipopolysaccharide (LPS). Our research findings demonstrated that LPS exposure induced depressive-like behaviors and disrupted mitophagy by diminishing the mitochondrial levels of PINK1/Parkin in the brains of mice. Furthermore, LPS exposure evoked the activation of the NLRP3 inflammasome, accompanied by a notable elevation in the concentrations of pro-inflammatory factors (TNF-α, IL-1β, and IL-6). Additionally, neuronal apoptosis was stimulated through the JNK/p38 pathway. The administration of BGP-15 effectively nullified the impact of LPS, corresponding to the amelioration of depressive-like phenotypes and restoration of mitophagy, prevention of neuronal injury and inflammation, and suppression of reactive oxygen species (ROS)-mediated NLRP3 inflammasome activation. Furthermore, we elucidated the involvement of mitophagy in BGP-15-attenuated depressive-like behaviors using the inhibitors targeting autophagy (3-MA) and mitophagy (Mdivi-1). Notably, these inhibitors notably counteracted the antidepressant and anti-inflammatory effects exerted by BGP-15. Based on the research findings, it can be inferred that the antidepressant properties of BGP-15 in LPS-induced depressive-like behaviors could potentially be attributed to the involvement of the mitophagy pathway. These findings offer a potential novel therapeutic strategy for managing MDD.
Given the extensive immunologic and virologic data available from ACTG 315, follow-up studies of this advanced-disease population are indicated to primarily ascertain the impact of long-term suppression of viral replication on immunologic reconstitution or re-education and the durability of the antiviral effects of HAART.

Patients continue their current ACTG 315 regimen of zidovudine plus lamivudine plus ritonavir in an open-label fashion while undergoing 6 weeks of extensive evaluations. Treatment decisions are based on baseline viral load (mean of 2 viral load measurements taken during 6-week evaluations). Patients with HIV-1 RNA less than 100 copies/ml continue the ACTG 315 regimen. Patients with HIV-1 RNA 100-3000 copies/ml may continue the ACTG 315 regimen or initiate a new HAART regimen selected by the local investigator or primary care physician. Patients with HIV-1 RNA greater than 3000 copies/ml initiate a new HAART regimen selected by the local investigator or primary care physician. \[AS PER AMENDMENT 4/10/00: Changes to regimens must be done in consultation with the study team. The team acknowledges that a viable regimen may not be available for a given patient when the plasma HIV RNA level is above 3,000 copies/ml. In this case, patients may remain on their failing regimen with evaluation every 8 weeks until a viable regimen becomes available to them.\] All patients are required to maintain a HAART regimen that contains at least 3 drugs, 1 of which is a protease inhibitor. \[AS PER AMENDMENT 3/5/01: All patients are required to maintain a HAART regimen that is approved by the protocol chairs.\] Zidovudine (ZDV), lamivudine (3TC), stavudine (d4T), didanosine (ddI), delavirdine (DLV), ritonavir (RTV), and saquinavir soft gel capsules (SQV sgc) are provided on-study. \[AS PER AMENDMENT 9/19/00: ZDV, 3TC, 3TC/ZDV combination tablet, d4T, ddI, DLV, RTV, and SQV sgc will be supplied by the protocol for 182 weeks.\] \[AS PER AMENDMENT 3/5/01: The following antiretroviral medications will be supplied by the protocol for Steps 1 and 2: ZDV, 3TC, 3TC/ZDV combination tablet, d4T, ddI, DLV, RTV, and SQV sgc.\] Therapy is continued for 54 weeks. \[AS PER AMENDMENT 10/6/98: The initial 54-week trial is followed by an additional 2 years of long-term evaluation. Also per this amendment, protocol therapy is initiated at Week 6.\] \[AS PER AMENDMENT 9/19/00: The initial 54-week trial is followed by an additional 2.5 years of long-term evaluation.\] \[AS PER AMENDMENT 3/5/01: Step 1 has an initial 54 weeks of treatment followed by 140 weeks of long-term follow-up. Step 2 has an additional 36 weeks of long-term follow-up. Patients who complete the final visit on Step 2 (Week 230) should return to the clinic 4 weeks after receiving the last dose of study-provided medication to complete the final evaluations.\] \[AS PER AMENDMENT 10/6/98: Patients may co-enroll in an immunology substudy.\] \[AS PER AMENDMENT 6/11/99: The immunology substudy is being piloted in 3 to 4 volunteers and may not proceed until the feasibility of the pilot project is reviewed.\]
Participants will be given a flat amount for submitting samples on time, and there is no increasing scale for maintaining samples at 0.00%BAC. Participants will be given positive reinforcement messaging regardless of the sample's results.
Adverse reactions have occurred with corticosteroid/anti-infective combination drugs which can be attributed to the corticosteroid component, the anti-infective component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available.

Reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitizations. The reactions due to the corticosteroid component are: elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing.

Corticosteroid-containing preparations have also been reported to cause perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, and conjunctival hyperemia have occasionally been reported following local use of steroids.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
The cervix was stained with iodine solution and the diseased lesion was visualized. LEEP or conization was performed to a depth of approximately 1.5 cm to resect disease in the cervical canal.